Monday, September 7, 2015

Off Label Uses/ Insider Trading

 Is Proxy Pharmaceutical Providing a Misleading Update on Property Portfolio?

Proxy Pharmaceuticals  (NASDAQ ****), a biotech firm with stipulation that allows many of it's innovations to be developed covertly has announced  one new  addition to its U.S. intellectual property portfolio. The U.S. Patent and Trademark Office  has issued an Issue Notification for U.S. Patent Applications directed to the use of a pharmaceutical composition comprising Ketamine for a host of therapeutic usage  that address important unmet medical needs concerning innovative treatment of anxiety, depression and pain management .
 Forward-looking statements( within the loose  meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934)  give companies a lot of wiggle room concerning full disclosure .Proxy Pharma which already has deals in the mega billions with neural prosthetics with the DOD and DARPA  has learned a thing or two about Defensive Innovation using the Securities Exchange to intentionally mislead those outside the company itself to be aware of the companies long range plans to market a product  and  may include statements that purposely diminish  future operating, financial or business performance . Forward-looking statements are often adjusted to mislead any stock holder but the few aware of the enormity  of any future acquisitions, dispositions, partnerships, license transactions or changes.

No comments:

Post a Comment